Navigation Links
Diabetes Gene Raises Odds of Lower Birth Weight
Date:7/29/2009

evious studies by European diabetes researchers, said Grant, had suggested that CDKAL1 was implicated in both lower birth weight and type 2 diabetes, and the current study, using a large sample size, reinforced that association.

Under the fetal insulin hypothesis, a slight underproduction of insulin, an important fetal growth factor, during the prenatal period may cause a baby to be born smaller. Low birth weight is already known to increase the risk of disease later in life, and the fetal insulin hypothesis proposes that the same gene that causes lower birth weight also increases the risk of developing type 2 diabetes.

"The mechanisms by which CDKAL1 may act are not well understood, but it is believed to reduce insulin secretion, and that underproduction contributes to type 2 diabetes," said Grant. He added that further research may investigate biological pathways on which the gene functions, and may also study whether it may influence the risk of developing other diseases in later life.

The National Institutes of Health, the Cotswold Foundation and The Children's Hospital of Philadelphia supported this study. Grant and Hakonarson, and their co-authors, are from both The Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brou
'/>"/>

SOURCE The Children's Hospital of Philadelphia
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. S.C. Medical Home Pilot for Diabetes Enrolls 1,110
2. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
3. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
4. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
5. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
6. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
7. Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
8. SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
9. Study Shows GSKs Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
10. Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
11. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- CytRx Corporation (NASDAQ: CYTR ), a ... that data regarding the Company,s Phase 2b global clinical ... tissue sarcoma (STS) will be presented in a moderated ... (CTOS) Annual Meeting which is being held October 15-18, ... the longer than expected survival of patients in the ...
(Date:10/16/2014)...  One of California,s most ... the Patient Advocate — this week recognized Kaiser Permanente,s ... state for the seventh consecutive year. The ... and Kaiser Permanente Southern California are the only health ... a four-star rating — the highest possible — for ...
(Date:10/16/2014)... YORK , Oct. 16, 2014 Curtis ... organizer is under 3 weeks away from hosting their co-located ... and Oral Drug Formulation Innovations Summit taking ... San Diego, CA. November,s ... development organizations in streamlining the bioequivalence testing process, as ...
Breaking Medicine Technology:CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 2Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 3Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2
... July 14 ERT (Nasdaq: ERES ) announced today that ... August 9, 2010 , after the market closes. After the release, the Company ... , , , ... participants should dial 1-800-860-2442 when calling within the United States or ...
... , HONOLULU , July 14 EnVivo ... on Alzheimer,s Disease (ICAD) results from its proprietary gamma-secretase modulator ... reduced amyloid plaque buildup which is believed to be a ... inflammation associated with Alzheimer,s disease. , ...
Cached Medicine Technology:ERT to Announce Second Quarter 2010 Results on August 9, 2010 2EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer's Disease 2
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from ... theme for FCPX filmmakers . , “Fun, cool, and ... Citrus theme” Says Christina Austin, CEO of Pixel Film Studios. ... , Citrus comes with all the tools needed for a ... transitions for added style, a title screen for an introduction, ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 Houston ... to present the key elements of his innovative ... professor to plastic surgery residents and faculty at ... , where he, too, was once a medical student. ... the largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... obstacles, research shows , TUESDAY, Feb. 16 (HealthDay News) ... seek treatment for post-traumatic stress disorder, researchers say. , ... Iraq and Afghanistan wars received diagnoses of post-traumatic stress ... the recommended treatment of 10 to 12 weekly sessions ...
... Gets ... ... 16, 2010 -- BusinessCard2 ™, a web-based personal brand management, marketing, and social ... The competition was established to recognize great work in open/social business and organizational design, ...
... confirm that combination hormone therapy increases the risk of heart ... toward an increased risk of heart disease during the first ... within 10 years of menopause, and a more marked elevation ... 10 years after menopause. Analyses indicate that overall a ...
... Survey found most people thought they were fine, while their ... rising rates of obesity and diabetes, a new survey has ... just fine - it,s everyone else who has the problem. ... people,s health "was going in the wrong direction." In contrast, ...
... ... recorded in global sequence databases is growing exponentially, and legal professionals and scientists doing ... discover IP sequence information across these databases. The free seminar includes lunch and roundtable ... (Vocus) ...
... ... contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for its hospital and ... ... east Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for ...
Cached Medicine News:Health News:BusinessCard2 Wins Social Business Innovation Award 2Health News:BusinessCard2 Wins Social Business Innovation Award 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 2Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 4Health News:Most Americans Think It's Others Who Are Unhealthy 2Health News:Most Americans Think It's Others Who Are Unhealthy 3Health News:GenomeQuest Hosts Seminar Focused On Web-based Searching for Patent Information Across Global Sequence Databases 2Health News:Premier Anesthesia Forges New Partnership with Texas Hospital 2
... fixation. Completely resorbable, it presented surgeons with ... the most thoroughly proven product of its ... with system enhancements that make it even ... system means that application of this proven ...
... The intra-operative MR system ... intra-operative tool for radiologists ... goal of the system ... valuable adjunct to standard ...
... ultrasound A-scan Sonomed-315 is intended for visualization ... detection of midline shifts in the brain, ... and easy to use, the Sonomed-315 offers ... A-scanning mode allows to identify the anatomic ...
... With Plasmaseal's Proteus device the two steps ... is injected into Proteus' single use disposable ... base unit. The operator touches a button, ... is separated by centrifugation. Then the integral ...
Medicine Products: